Your session is about to expire
← Back to Search
Stem Cell Transplant for Blood Cancer
Study Summary
This trial is testing a new combination of chemotherapy and low-dose radiation to see if it is safe and effective in treating bone marrow cancer. The CliniMACS device is approved for one type of T cell depletion but not the type being studied in this trial. This trial will help determine if the CliniMACS device should be approved for the other type of T cell depletion.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 77 Patients • NCT01251575Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a stem cell transplant from a donor.I am HIV positive.I have tested positive for HTLV-1.I am able to care for myself and am up more than 50% of my waking hours.I do not have a perfect 10/10 HLA match donor.My health is too poor for normal activities or treatments.I am 18 years old or older.My heart, liver, kidneys, and lungs are all working well.I do not have an active, uncontrolled infection.I have a high-risk blood disorder.I have received radiation therapy with a high dose.
- Group 1: Patients with Myeloid Malignancies & Aplastic Anemia
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there currently an opportunity for individuals to join this clinical experiment?
"Per the information on clinicaltrials.gov, enrollment for this medical study is still ongoing. It was originally posted in May of 2018 and last amended 21st January 2022."
What previous research has been produced concerning Allogeneic Hematopoietic Stem Cell Transplantation?
"The earliest documented research on Allogeneic Hematopoietic Stem Cell Transplantation occurred in 1993 at the NIH Clinical Centre. A total of 1848 studies have since been completed, with 1155 live trials currently underway; many are located throughout New york City."
What medical ailments can be alleviated by Allogeneic Hematopoietic Stem Cell Transplantation?
"Allogeneic Hematopoietic Stem Cell Transplantation is a viable course of action for treating lung cancer, as well as multiple sclerosis, b-cell lymphomas, and polyangium."
What is the aggregate size of participants being involved in this clinical research?
"Affirmative. According to clinicaltrials.gov, this medical research project is still open for enrollment. The trial was initially listed on May 9th 2018 and most recently edited on January 21st 2022 with a target of 15 participants between two sites."
Has the FDA accepted Allogeneic Hematopoietic Stem Cell Transplantation as a legitimate course of treatment?
"Our team at Power evaluated the safety of Allogeneic Hematopoietic Stem Cell Transplantation and deemed it a 1 due to this being an early-phase trial with limited evidence for efficacy or risk."
Share this study with friends
Copy Link
Messenger